Risk of recurrence, prognosis, and follow‐up for Danish women with cervical cancer in 2005‐2013: A national cohort study

Taarnhøj, Gry Assam; Christensen, Ib Jarle; Lajer, Henrik; Fuglsang, Katrine; Jeppesen, Mette Moustgaard; Kahr, Henriette Strøm; Høgdall, Claus

doi:10.1002/cncr.31165

Cited by 35 publications

(45 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…► Cytology and human papillomavirus (HPV) detection are recommended at 12 and 24 months, and then yearly after fertilitysparing surgery. [35][36][37] ► Imaging studies are not routinely recommended but are indicated in women with symptoms. 20 High Risk Up to 30% of patients with locally advanced cervical cancers will relapse after complete response to primary treatment.…”

Section: Telemedicine Risk-stratified Surveillance By Disease Site Cementioning

confidence: 99%

Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19)

Mancebo

Solé-Sedeño

Membrive

et al. 2020

Int J Gynecol Cancer

View full text Add to dashboard Cite

The SARS-CoV-2 (COVID-19) pandemic has significantly impacted the management of patients with gynecologic cancers. Many centers have reduced access to routine visits to avoid crowded waiting areas and specially to reduce the infection risk for oncologic patients. The goal of this review is to propose a surveillance algorithm for patients with gynecologic cancers during the COVID-19 pandemic based on existing evidence and established guidelines. It is time to consider strategies based on telemedicine and to adapt protocols in this new era. We hereby propose a strategy for routine surveillance both during and beyond the pandemic.

show abstract

Section: Telemedicine Risk-stratified Surveillance By Disease Site Cementioning

confidence: 99%

Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19)

Mancebo

Solé-Sedeño

Membrive

et al. 2020

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…However only 4-5% will have pelvic recurrences and only 1-2% can be salvaged 28,31,32 , although this has increased slightly with cyberknife and other techniques. In a large Danish national cohort study of 1523 patients with low-risk cervical cancer, of those with recurrent disease, 67.5% experienced a symptomatic recurrence 30 Other studies have shown similar rates of symptomatic recurrent cervical cancer 24 . Therefore, as the majority present with symptoms, PIFU appears to be reasonable for low-risk patients.…”

Section: Endometrial Cancermentioning

confidence: 95%

“…However, vaginal vault cytology should not be performed following treatment for FIGO stage ≥IA2 as it does not add significantly to the detection of recurrent disease 25, [27][28] . These patients have a 5-year risk of recurrence of 5.8-8% 27,[29][30][31] . However only 4-5% will have pelvic recurrences and only 1-2% can be salvaged 28,31,32 , although this has increased slightly with cyberknife and other techniques.…”

Section: Endometrial Cancermentioning

confidence: 99%

“…At the follow-up appointment, symptoms should be assessed and a physical examination should be carried out in the first 3 years from completing treatment in patients with FIGO stage 2-4, as this is the most common time period in which recurrent disease develops 30 . In years 4 and 5, in the absence of recurrent disease, patients could have the option of moving to a combination of telephone follow up with CA125 serial measurements, if deemed suitable by their clinician.…”

Section: Endometrial Cancermentioning

confidence: 99%

See 1 more Smart Citation

British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)

Newton

Nordin

Rolland

et al. 2020

Int J Gynecol Cancer

View full text Add to dashboard Cite

The National Cancer Survivorship Initiative through the National Health Service (NHS) improvement in the UK started the implementation of stratified pathways of patient-initiated follow-up (PIFU) across various tumor types. Now the initiative is continued through the Living With and Beyond Cancer program by NHS England. Evidence from non-randomized studies and systematic reviews does not demonstrate a survival advantage to the long-established practice of hospital-based follow-up regimens, traditionally over 5 years. Evidence shows that patient needs are inadequately met under the traditional follow-up programs and there is therefore an urgent need to adapt pathways to the needs of patients. The assumption that hospital-based follow-up is able to detect cancer recurrences early and hence improve patient prognosis has not been validated. A recent survey demonstrates that follow-up practice across the UK varies widely, with telephone follow-up clinics, nurse-led clinics and PIFU becoming increasingly common. There are currently no completed randomized controlled trials in PIFU in gynecological malignancies, although there is a drive towards implementing PIFU. PIFU aims to individualize patient care, based on risk of recurrence and holistic needs, and optimizing resources. The British Gynaecological Cancer Society wishes to provide the gynecological oncology community with guidance and a recommendations statement regarding the value, indications, and limitations of PIFU in endometrial, cervical, ovarian, and vulvar cancers in an effort to standardize practice and improve patient care.

show abstract

“…Despite substantial development in understanding the molecular mechanisms and treatment for CC in recent years, the overall 5-year survival rates are not very encouraging [5,6]. The most com-DOI: 10.1159/000487595 mon therapeutic methods for CC are surgery, radiotherapy, and chemotherapy [7][8][9]. However, due to a lack of effective biomarker screening and restricted diagnosis technology, more sensitive and specific markers for diagnosis at early stage and more efficient and safer treatments are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Four Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting Cervical Cancer

Sun

Wang

Zhao

et al. 2018

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aims: Circulation long non-coding RNAs (lncRNAs) have emerged recently as major players in tumor biology and might be applied for cancer diagnosis, prognosis, or potential therapeutic targets. In this study, we aimed to explore whether the circulation lncRNA could predict the tumorigenesis of surgical squamous cervical cancer (CC). Methods: In this study, we applied the lncRNA microarray to screen the potential biomarker for CC. Real-time quantitate polymerase chain reaction was conducted for further validation in a larger sample size. The multi-stage validation and risk score formula analysis were used to examine the sensitivity and specificity. Results: We discovered 4 lncRNAs including HOTAIR, PVT1, XLOC_000303, and AL592284.1, which were upregulated in CC comparing with the cancer-free controls. Further, the receiver operating characteristic curve (ROC) analysis by risk score formula revealed the combined 4 factors with a high diagnostic ability with the area under ROC curve value of 0.875 and 0.958 in training set and validation set respectively. We finally confirmed the stable detection of the 4 lncRNAs by 5 cycles of freezing and thawing. Conclusion: HOTAIR, PVT1, XLOC_000303, and AL592284.1 might be the potential biomarkers for predicting the tumorigenesis of CC in the future.

show abstract

Risk of recurrence, prognosis, and follow‐up for Danish women with cervical cancer in 2005‐2013: A national cohort study

Cited by 35 publications

References 26 publications

Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19)

Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19)

British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)

Four Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting Cervical Cancer

Contact Info

Product

Resources

About